Enhanced melanoma cancer prevention by novel melanotropins
View Patent ↗A gamma-melanocyte stimulating hormone (γ-MSH) derivative having improved stability, selectivity and bioavailabilty. The γ-MSH derivative is selective for the melanocortin-1 receptor (MC1 R) and is deliverable to skin cells via topical or transdermal delivery. The γ-MSH derivative is made up of naturally occurring amino acids for stimulating melanin from within for photoprotection of human skin against ultraviolet radiation damage.
1. A melanocortin 1 receptor (MC1R) peptide ligand comprising naturally occurring amino acids, wherein the MC1R peptide ligand is according to SEQ ID NO. 1:
(SEQ ID NO: 1)
H-Tyr 1 -Val 2 -Waa 3 -Gly 4 -Xaa 5 -Phe 6 -Yaa 7 -Zaa 8 -Asp 9 -
Arg 10 -Phe 11 -Gly 12 -R1
wherein Waa is a Met, Ile, or Leu, Xaa is a His or Pro, Yaa is an Arg or Leu, and Zaa is a Phe or Trp, and wherein R1 of the C-terminal is —NH 2 , or —OH, with the caveat that Waa is not Met, Xaa is not His, Yaa is not Arg, Zaa is not Trp, and R1 is not OH simultaneously.
2. The MC1R peptide ligand according to claim 1 , wherein Waa is Leu, Xaa is His, Yaa is Leu, Zaa is Phe, and R1 is —NH 2 .
3. The MC1R peptide ligand according to claim 1 , wherein the MC1R peptide ligand is selected from a group consisting of:
(SEQ ID NO: 2)
H-Tyr-Val-Leu-Gly-Pro-Phe-Arg-Trp-Asp-Arg-Phe-Gly-
NH 2 ;
(SEQ ID NO: 5)
H-Tyr-Val-Leu-Gly-His-Phe-Leu-Phe-Asp-Arg-Phe-Gly-
NH 2 ;
(SEQ ID NO: 6)
H-Tyr-Val-Leu-Gly-Pro-Phe-Leu-Trp-Asp-Arg-Phe-Gly-
NH 2 ;
(SEQ ID NO: 7)
H-Tyr-Val-Leu-Gly-Pro-Phe-Leu-Phe-Asp-Arg-Phe-Gly-
NH 2 ;
(SEQ ID NO: 8)
H-Tyr-Val-Leu-Gly-His-Phe-Arg-Trp-Asp-Arg-Phe-Gly-
OH
(SEQ ID NO: 9)
H-Tyr-Val-Leu-Gly-His-Phe-Arg-Trp-Asp-Arg-Phe-Gly-
NH 2 ;
and
(SEQ ID NO: 10)
H-Tyr-Val-Met-Gly-Pro-Phe-Arg-Trp-Asp-Arg-Phe-Gly-
NH 2 .
4. The MC1R peptide ligand of claim 1 , wherein the MC1R peptide ligand is selective for MC1R, wherein the MC1R peptide ligand is an agonist of MC1R.
5. The MC1R peptide ligand of claim 1 , wherein the MC1R peptide ligand is at least twice as selective for MC1R than MC3R, MC4R, or MC5R.
6. The MC1R peptide ligand of claim 1 , wherein the MC1R peptide ligand is capable of stimulating melanin production.
7. A pharmaceutical composition for preventing skin cancer, said composition comprising a melanocortin 1 receptor (MC1R) peptide ligand in a pharmaceutically acceptable carrier, wherein the MC1R peptide ligand comprises naturally occurring amino acids, wherein the MC1R peptide ligand is according to SEQ ID NO. 1:
(SEQ ID NO: 1)
H-Tyr 1 -Val 2 -Waa 3 -Gly 4 -Xaa 5 -Phe 6 -Yaa 7 -Zaa 8 -Asp 9 -
Arg 10 -Phe 11 -Gly 12 -R1
wherein Waa is a Met, Ile, or Leu, Xaa is a His or Pro, Yaa is an Arg or Leu, and Zaa is a Phe or Trp, and wherein R1 of the C-terminal is —NH 2 , or —OH, with the caveat that Waa is not Met, Xaa is not His, Yaa is not Arg, Zaa is not Trp, and R1 is not OH simultaneously, and wherein the MC1R peptide ligand is selective for MC1R, and wherein the MC1R peptide ligand is an agonist of MC1R, wherein the MC1R peptide ligand is capable of stimulating melanin production, thereby preventing skin cancer.
8. A pharmaceutical composition for stimulating melanin production, said composition comprising a melanocortin 1 receptor (MC1R) peptide ligand in a pharmaceutically acceptable carrier, wherein the MC1R peptide ligand comprises naturally occurring amino acids, wherein the MC1R peptide ligand is according to SEQ ID NO. 1:
(SEQ ID NO: 1)
H-Tyr 1 -Val 2 -Waa 3 -Gly 4 -Xaa 5 -Phe 6 -Yaa 7 -Zaa 8 -Asp 9 -
Arg 10 -Phe 11 -Gly 12 -R1
wherein Waa is a Met, Ile, or Leu, Xaa is a His or Pro, Yaa is an Arg or Leu, and Zaa is a Phe or Trp, and wherein R1 of the C-terminal is —NH 2 , or —OH, with the caveat that Waa is not Met, Xaa is not His, Yaa is not Arg, Zaa is not Trp, and R1 is not —OH simultaneously, and wherein the MC1R peptide ligand is selective for MC1R, and wherein the MC1R peptide ligand is an agonist of MC1R, wherein the MC1R peptide ligand is capable of stimulating melanin production.
9. The pharmaceutical composition of claim 7 , wherein the MC1R peptide ligand is present in an amount ranging from about 0.001-20 wt % of the pharmaceutical composition.
10. The pharmaceutical composition of claim 7 , wherein the pharmaceutical composition is administered topically for delivering the MC1R peptide ligand through skin.
11. The pharmaceutical composition according to claim 10 , wherein the pharmaceutical composition is in a form selected from a group consisting of a gel, a hydrogel, a water-in-oil emulsion, an oil-in-water emulsion, a cream, a lotion, an ointment, a spray, a foam, a multi-emulsion, and a liposome.
12. The pharmaceutical composition according to claim 10 , wherein the pharmaceutical composition is in a form of a patch, said patch comprising an impenetrable outer layer, and a permeable inner layer, wherein the outer layer and the inner layer form a reservoir for storing the pharmaceutical composition, wherein when the patch is applied on a skin of mammal, the pharmaceutical composition permeates through the inner layer and the MC1R peptide ligand pass through the skin.
13. The pharmaceutical compositions of claim 7 , wherein the MC1R peptide ligand is selected from a group consisting of:
(SEQ ID NO: 2)
H-Tyr-Val-Leu-Gly-Pro-Phe-Arg-Trp-Asp-Arg-Phe-Gly-
NH 2 ;
(SEQ ID NO: 5)
H-Tyr-Val-Leu-Gly-His-Phe-Leu-Phe-Asp-Arg-Phe-Gly-
NH 2 ;
(SEQ ID NO: 7)
H-Tyr-Val-Leu-Gly-Pro-Phe-Leu-Phe-Asp-Arg-Phe-Gly-
NH 2 ;
(SEQ ID NO: 8)
H-Tyr-Val-Leu-Gly-His-Phe-Arg-Trp-Asp-Arg-Phe-Gly-
OH
(SEQ ID NO: 9)
H-Tyr-Val-Leu-Gly-His-Phe-Arg-Trp-Asp-Arg-Phe-Gly-
NH 2 ;
and
(SEQ ID NO: 10)
H-Tyr-Val-Met-Gly-Pro-Phe-Arg-Trp-Asp-Arg-Phe-Gly-
NH 2 .
14. The pharmaceutical composition of claim 8 , wherein the MC1R peptide ligand is present in an amount ranging from about 0.001-20 wt % of the pharmaceutical composition.
15. The pharmaceutical composition of claim 8 , wherein the pharmaceutical composition is administered topically for delivering the MC1R peptide ligand through skin.
16. The pharmaceutical composition of claim 15 , wherein the pharmaceutical composition is in a form selected from a group consisting of a gel, a hydrogel, a water-in-oil emulsion, an oil-in-water emulsion, a cream, a lotion, an ointment, a spray, a foam, a multi-emulsion, and a liposome.
17. The pharmaceutical composition of claim 15 , wherein the pharmaceutical composition is in a form of a patch, said patch comprising an impenetrable outer layer, and a permeable inner layer, wherein the outer layer and the inner layer form a reservoir for storing the pharmaceutical composition, wherein when the patch is applied on a skin of mammal, the pharmaceutical composition permeates through the inner layer and the MC1R peptide ligand pass through the skin.
18. The pharmaceutical composition of claim 8 , wherein the MC1R peptide ligand is selected from a group consisting of:
(SEQ ID NO: 2)
H-Tyr-Val-Leu-Gly-Pro-Phe-Arg-Trp-Asp-Arg-Phe-Gly-
NH 2 ;
(SEQ ID NO: 5)
H-Tyr-Val-Leu-Gly-His-Phe-Leu-Phe-Asp-Arg-Phe-Gly-
NH 2 ;
(SEQ ID NO: 7)
H-Tyr-Val-Leu-Gly-Pro-Phe-Leu-Phe-Asp-Arg-Phe-Gly-
NH 2 ;
(SEQ ID NO: 8)
H-Tyr-Val-Leu-Gly-His-Phe-Arg-Trp-Asp-Arg-Phe-Gly-
OH
(SEQ ID NO: 9)
H-Tyr-Val-Leu-Gly-His-Phe-Arg-Trp-Asp-Arg-Phe-Gly-
NH 2 ;
and
(SEQ ID NO: 10)
H-Tyr-Val-Met-Gly-Pro-Phe-Arg-Trp-Asp-Arg-Phe-Gly-
NH 2 .
19. A method of preventing skin cancer in a mammal, said method comprising administering to the mammal a therapeutically effective amount of a melanocortin 1 receptor (MC1R) peptide ligand according to claim 1 , wherein the MC1R peptide ligand is selective for MC1R, wherein the MC1R peptide ligand is capable of stimulating melanin production, thereby preventing skin cancer.
20. A method of stimulating melanin production in a mammal, said method comprising administering to the mammal a melanocortin 1 receptor (MC1R) peptide ligand according to claim 1 in an amount sufficient to stimulate melanin production, wherein the MC1R peptide ligand is selective for MC1R.